In addition, a study by Nygaard et al. investigated the prognostic value of plasma ctDNA in NSCLC patients with mutated KRAS, showing that patients with advanced NSCLC and a detectable KRAS ctDNA had a significantly shorter OS (4.8 months vs. 9.5 months) and PFS (3.0 months vs. 5.6 months) compared to the wild type carriers, confirming the independent negative prognostic effect of baseline KRAS positive mutational status [57]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.